Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The news was good and this was played and tomorrow is another day in the AIM casino. After 9 years here, I was hoping the rise would have lasted a bit longer for me to reduce more losses a bit more or maybe breakeven, just have to wait a bit longer. Where is ST now, he appears to have gone silent? GLA
guess he made his money and ran
Ok, while Iām still trying to make sense of all thatās happened today, I wanted to post so that people donāt think I have cut and run. I havenāt. Looking at the results, they are good. I canāt pretend that I wasnāt a little disappointed this morning, as I was hoping for very good or excellent, with some partial reductions thrown in. I agree with mathsprof about the trial design, in that it couldnāt show off the full potential of this drug. It doesnāt mean the drug is bad though. 54% success rate is a good rate in oncology trials. I donāt understand why the maximum tolerated dose wasnāt reached in the trial, as I assumed the adverse event would have been at 16mg/kg...which should have been why we knew they only went to 8. This will only become apparent in the full results, I guess. I would hope for some guidance from Suzy as to which direction we go in from here, as thereās more going on here than this RNS suggests. Also thereās more to 201 than this suggests too. Why would we need to redo the phase 1? Iāve been trying to interpret the wording of the RNS as the 8mg/kg dose worked. I genuinely thought this morning that the sp would go up, but not the two and threefold increases some were predicting...I didnāt expect it to go down and to the extent it did.
But anyway, Iām still mulling this over and feeling a little bit delicate about whatās happened today, but am definitely still in, as this has legs, in my opinion. Oh, and the people that are not in this share, or that never post but have come here to gloat today...itās easy to pick holes in things when you are in possession of the results...anybody can do that. Itās not constructive and you can respectfully go and do one.
Grace
You have cheered me up with your last line, I think this will bounce back :)
Go and have a gin :)
Grace, just found your message! It was buried!
Nice to read a calm(ish) post. I did enjoy the final remarks.
Plenty of frustrated people today, hopefully tomorrow things will a bit quieter after everyone has had the chance to sleep on it.
Onwards and upwards!
Grace83, 18:16; "I donāt understand why the maximum tolerated dose wasnāt reached in the trial, as I assumed the adverse event would have been at 16mg/kg...which should have been why we knew they only went to 8. "
Grace, I have it in mind that at the higher doses the volume required to be injected became problematic. As I remember it, all doses were by injection. Sorry I can't provide a reference for this.
From what I understand, there were reaction issues to the patients at the area of injection.
Asked the good lady to have a look at RNS - sheās lead oncology pharmacist at her hospital so respect her feedback above the vast majority on this board.
Didnāt sell any of my 112k shares today, btw! DYOR!!
I found this article this morning
https://pharmaphorum.com/news/valirx-eyes-partnerships-as-first-val201-study-hits-the-mark/
Most others have posted it, but it is good to see that the results have attracted some media attention.
Looking forward to a better day today. Gla
Bankfool- some big money came in sub 30p hence it dropped to get those orders in. Should be a +25% day today imo. 42p close imo
Endometriosis market $2 billion per year
VAL 301 being trialled by global pharma.
Now safety profile of 201 has been met, can be applied to 301 too. Makes chance of something happening soon much greater imo
Eyeguy, 25% up sounds excessive, but a 40p (ish) sounds about right to me as I think this has been oversold and there was news of substance yesterday, so this could be a big bounce today.
I did notice the big value buys and sells. Not too fussed by the sales as they were quickly absorbed by the buyers.
More important is fact that there were big value buys which means that the big boys haven't sold out and are running for cover, rather they are taking advantage of the dip.
If they buys had all been tiny I would have been worried (smaller timers calling it wrong and compounding the error) but this isn't the case. Gla
Bank
If they can drop it 50% in a day the other way can also happen.
The start maybe furious letās see.
OR those big buys were the shorters closing their position.
Looking at the charts on Friday it was clear that from a technical perspective it was overbought and heavy and a retrace was needed. The only thing that would have countered a retrace was a stonking rns with someone that we didnāt already know. Ie, a deal.
That didnt come. So the retrace happened.
great great article
sp will bounce back substantially
Valirx eyes partnerships as first VAL201 study hits the mark
. after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trValirxā recently-appointed chief executive Dr. Suzy Dilly pointed out that the data has been āgenerated using the utmost caution in sequentially dosing patientsā and that future studies will try to āconfirm these early indications of a positive response rate.ā